Lancet Infectious Diseases最新文献

{"title":"Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial","authors":"William H K Schilling, Podjanee Jittamala, Phrutsamon Wongnak, James A Watson, Simon Boyd, Viravarn Luvira, Tanaya Siripoon, Thundon Ngamprasertchai, Elizabeth M Batty, Ellen Beer, Shivani Singh, Tanatchakorn Asawasriworanan, Timothy Seers, Koukeo Phommasone, Terry John Evans, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Wanassanan Madmanee, Nicholas J White","doi":"10.1016/s1473-3099(25)00482-7","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00482-7","url":null,"abstract":"<h3>Background</h3>Ensitrelvir is an oral antiviral treatment for COVID-19 with the same molecular target (the main protease) as ritonavir-boosted nirmatrelvir—the current oral first-line treatment. We aimed to compare the clinical antiviral effects of the two drugs.<h3>Methods</h3>In an open-label, phase 2, randomised, controlled, adaptive pharmacometric platform trial, low-risk adult outpatients aged 18–60 years with early symptomatic COVID-19 (<4 days of symptoms) were recruited from hospital acute respiratory infection clinics in Thailand and Laos. Patients were randomly assigned in blocks (block sizes depended on the number of interventions available) to one of eight treatment groups, including oral ensitrelvir and oral ritonavir-boosted nirmatrelvir at standard doses, both given for 5 days, and no study drug. The primary endpoint was the oropharyngeal SARS-CoV-2 viral clearance rate assessed between day 0 and day 5 in the modified intention-to-treat population (defined as patients with at least 2 days of follow-up). Patients had four oropharyngeal swabs taken on day 0 and two swabs taken daily from days 1 to 7, then on days 10 and 14. Viral clearance rates were derived under a Bayesian hierarchical linear model fitted to log<sub>10</sub> viral densities in standardised paired oropharyngeal swab eluates taken daily over the 5 days (14 samples). An individual patient data meta-analysis of all small molecule drugs evaluated in this platform trial using published results was also performed, adjusting for temporal trends in viral clearance. This trial is registered at <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, <span><span>NCT05041907</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>.<h3>Findings</h3>Between March 17, 2023, and April 21, 2024, 604 of 903 patients enrolled were concurrently assigned to the three treatment groups (ensitrelvir n=202; ritonavir-boosted nirmatrelvir n=207; no study drug n=195). Median estimated SARS-CoV-2 clearance half-lives were 5·9 h (IQR 4·0–8·6) with ensitrelvir, 5·2 h (3·8–6·6) with nirmatrelvir, and 11·6 h (8·1–14·5) with no study drug. Viral clearance following ensitrelvir was 82% faster (95% credible interval 61–104) than no study drug and 16% slower (5–25) than ritonavir-boosted nirmatrelvir. In the meta-analysis of all unblinded small molecule drugs evaluated in the platform trial, nirmatrelvir and ensitrelvir had the largest antiviral effects (1157 patients). Viral rebound occurred in 15 (7%) of 207 patients in the nirmatrelvir group and 10 (5%) of 202 in the ensitrelvir group (p=0·45).<h3>Interpretation</h3>Both ensitrelvir and nirmatrelvir accel","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"73 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145261049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Infect Dis 2025; 25: e498","authors":"","doi":"10.1016/s1473-3099(25)00629-2","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00629-2","url":null,"abstract":"<em>Lateef S. A rare case of rabies-like Australian bat lyssavirus infection.</em> Lancet Infect Dis <em>2025;</em> 25: <em>e498</em>—In this Newsdesk, the spelling of author Samaan Lateef was incorrect. This correction has been made as of Oct 10, 2025.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"122 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment","authors":"Choi Ming Hong, Ivan Fan Ngai Hung","doi":"10.1016/s1473-3099(25)00549-3","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00549-3","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"57 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145261048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)","authors":"Sophie Yacoub, Anastasia Demidova, Xin Hui S Chan, Ali Ajam, Dina Baimukhambetova, Andreij Horn, Evgeniia Kakotkina, Mark Kosenko, Aigun Mursalova, Jennifer Ilo Van Nuil, Chi Le Phuong, Lin Xiao, Sudeep Adhikari, Juan David Alzate Alvarez, Kathryn B Anderson, Panisadee Avirutnan, Stephanie Buchholz, Richa Chandra, Aileen Y Chang, Ho Quang Chanh","doi":"10.1016/s1473-3099(25)00500-6","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00500-6","url":null,"abstract":"Dengue, caused by any one of four distinct virus serotypes, is the most rapidly spreading mosquito-borne viral disease worldwide. It is a primary arboviral infection with increasing global incidence, driven by climate change, urbanisation, and the expanding range of Aedes mosquito vectors. Despite growing research interest, outcome and measurement instrument heterogeneity in dengue clinical trials remains high, limiting comparability and evidence synthesis. This project aimed to develop a globally relevant Core Outcome Measurement Set (COMS) for use in dengue clinical trials through international consensus. This consensus study followed core outcome measures in effectiveness trials and Core Outcome Set-Standards for Development (COS-STAD) guidelines and was conducted in two phases. Phase 1 focused on developing a Core Outcome Set (COS) through four steps: (1) a systematic literature review; (2) qualitative interviews with people with lived experience of dengue; (3) review by the management group and steering committee; (4) a two-round modified Delphi survey and structured online consensus meetings to finalise the COS for hospitalised and early stages of dengue disease. Input from critical care experts informed recommendations for the intensive care unit (ICU) and high dependency unit COS. Phase 2 consisted of a further two steps: (1) targeted review of outcome measurement instruments; and (2) a hybrid international consensus workshop to finalise the COMS. The agreed COMS for hospitalised dengue included seven outcomes; the early stage dengue COS included these outcomes plus four more. For critical care trials, use of existing ICU-specific COS was recommended. Unified definitions were developed for nine clinician-reported outcomes. The DEN-CORE COMS provides a consensus-based framework for harmonising outcome selection and measurement in dengue trials, improving comparability and supporting policy and clinical decision making.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"56 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xpert-Ultra for diagnosing asymptomatic tuberculosis","authors":"Xia Yu, Hairong Huang","doi":"10.1016/s1473-3099(25)00563-8","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00563-8","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"9 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study","authors":"Joowhan Sung, Mariam Nantale, Annet Nalutaaya, Patrick Biché, James Mukiibi, Joab Akampurira, Rogers Kiyonga, Francis Kayondo, Michael Mukiibi, Caitlin Visek, Caleb E Kamoga, David W Dowdy, Achilles Katamba, Emily A Kendall","doi":"10.1016/s1473-3099(25)00536-5","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00536-5","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Systematic screening for tuberculosis using Xpert Ultra can generate trace results of uncertain significance. Additional microbiological testing in this context is often negative, but untreated individuals might still progress to culture-positive disease. We aimed to estimate the 2-year risk of tuberculosis among screened participants with trace-positive sputum (PWTS).&lt;h3&gt;Methods&lt;/h3&gt;In this longitudinal follow-up study, we conducted Ultra-based systematic screening for tuberculosis in Kampala, Uganda, from Feb 2, 2021, to April 27, 2024, enrolling PWTS as well as participants who were Ultra-positive or Ultra-negative controls. Recruitment occurred primarily through community-based screening events and door-to-door screening. Ultra sputum testing was offered to individuals aged 15 years or older who were not on active tuberculosis treatment, regardless of their symptoms. All PWTS, as well as age-matched and sex-matched participants with negative screening results and consecutive participants with positive screening results, were recruited. Participants underwent extensive initial evaluation, and untreated PWTS and negative-control participants were followed up with re-testing for up to 24 months. Our primary outcome was the cumulative hazard of tuberculosis among PWTS, using two definitions of tuberculosis: one incorporating clinician judgement and one strictly microbiological. We then compared hazards between PWTS and negative-control participants. We also assessed whether the presence of symptoms or chest x-ray abnormalities at baseline were associated with tuberculosis diagnosis during follow-up in PWTS.&lt;h3&gt;Findings&lt;/h3&gt;We screened 31 505 people for tuberculosis in Uganda using sputum Xpert Ultra as an initial test through event-based and door-to-door screening. We enrolled 128 PWTS and 139 age-matched and sex-matched control participants who were Ultra-negative (negative-control participants) into prospective cohorts and 110 control participants who were Ultra-positive (more than trace) for cross-sectional comparison. Of 128 PWTS, 79 (62%) were male, 49 (38%) were female, and 19 (15%) were HIV positive; 45 (35%) were recommended for treatment upon enrolment, eight (6%) were lost to follow-up within 3 months, and 75 (56%) were followed up for a median of 706 days (IQR 344–714), of whom 19 (25%) were recommended for treatment during follow-up. The cumulative hazard of tuberculosis among PWTS not treated at baseline was 0·24 (95% CI 0·15–0·40) at 1 year and 0·33 (0·21–0·54) at 2 years, versus 0·03 (0·01–0·10) at 2 years for negative-control participants. Hazards were similar for microbiologically defined tuberculosis (0·36 [95% CI 0·22–0·58] for PWTS &lt;em&gt;vs&lt;/em&gt; 0·02 [0·01–0·10] for negative-control participants at 2 years). Tuberculosis diagnosis during follow-up was strongly associated with atypical baseline chest x-ray (ie, interpreted by radiologists as having any abnormality; hazard ratio 14·6 [95% CI 3·3–63·8]) but not w","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"108 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccines and religion in Zimbabwe | Religion and COVID-19 Vaccination in Zimbabwe, Tenson Muyambo, Fortune Sibanda, Ezra Chitando (Eds.), Routledge (2025), p. 270, £36·19, ISBN: 978-1032483603","authors":"Kate Wilcock","doi":"10.1016/s1473-3099(25)00618-8","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00618-8","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"7 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Emerging Resistance Index: tracking early resistance to new antibiotics","authors":"Jacopo Garlasco, Fabiana Arieti, Matteo Morra, Maela Tebon, Diego Ortiz, Maria Diletta Pezzani, Karin Odoj, Federica Manco, Alessandro Cassini, Stephan Harbarth, Elisabeth Presterl, Biljana Carevic, Gunnar Kahlmeter, Karin Thursky, Paola Morelli, Stefan Hagel, Alessia Savoldi, Evelina Tacconelli","doi":"10.1016/s1473-3099(25)00501-8","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00501-8","url":null,"abstract":"The high clinical burden of antimicrobial resistance (AMR) and the dwindling antibiotic pipeline demand standardised tools to monitor resistance development to new antibiotics. The Emerging Resistance Index (ERI) is a novel quantitative tool designed to track resistance to newly developed antibiotics. The ERI incorporates various parameters: AMR pooled proportions and trends, availability of AMR and antimicrobial consumption surveillance systems, time lag between antibiotic approval and resistance detection, and the average annual number of outbreaks caused by resistant strains. AMR and antimicrobial consumption data on 13 new antibiotics were extracted by reviewing the literature and the reports from 38 surveillance systems included in the European Clinical Research Alliance on Infectious Diseases–The Epidemiology Network central data repository, encompassing 27 EU countries, four European Free Trade Association countries, and the UK. Our analysis revealed rapid resistance development to all new Gram-negative-targeting antibiotics, with particularly high ERI values for imipenem–relebactam and cefiderocol. Combinations of old β-lactams with novel inhibitors were especially prone to rapid resistance development. The ERI could offer a quantitative and dynamic tool for monitoring resistance trends. Also, the ERI could support more timely surveillance efforts, inform antibiotic policy decisions, and aid in prioritising antibiotic research and development.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"31 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial","authors":"David L Paterson, Helmi Sulaiman, Po-Yu Liu, Mark D Chatfield, Mesut Yilmaz, Zeti Norfidiyati Salmuna, Mohd Zulfakar Mazlan, Siriluck Anunnatsiri, Rujipas Sirijatuphat, Darunee Chotiprasitsakul, David C Lye, Jyoti Somani, Shirin Kalimuddin, Abdullah T Aslan, Visanu Thamlikitkul, Yi-Tzu Lee, Ya-Sung Yang, Yi-Tsung Lin, Wan Nurliyana Wan Ramli, Chien-Hao Tseng, Patrick N A Harris","doi":"10.1016/s1473-3099(25)00469-4","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00469-4","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Bloodstream infections caused by bacteria with carbapenem resistance are associated with high mortality. Cefiderocol has broad in vitro activity against carbapenem-resistant Gram-negative bacilli. We aimed to assess whether cefiderocol was non-inferior or superior to standard-of-care antibiotics in preventing mortality in patients with bloodstream infection caused by Gram-negative bacilli.&lt;h3&gt;Methods&lt;/h3&gt;The GAME CHANGER trial was an open-label, parallel-group, randomised clinical trial in which patients with health-care-associated or hospital-acquired Gram-negative bloodstream infection were recruited from 17 tertiary hospitals with more than 500 beds in Australia, Malaysia, Singapore, Taiwan, Thailand, and Türkiye. Adult patients (aged ≥21 years in Singapore or ≥18 years elsewhere) with positive blood cultures and Gram-negative bacilli seen on Gram stain were eligible. Participants were randomly assigned in a 1:1 ratio to cefiderocol (2 g intravenously every 8 h) or standard of care (chosen by the patient's clinical team) using an online randomisation tool with strata defined by severity of comorbidities and region, with random permuted blocks of unequal size. Patients, treating clinicians, and site investigators were not masked to treatment. The primary outcome was all-cause mortality at 14 days after randomisation. All outcomes were analysed in participants who received at least one dose of assigned antibiotic, grew an aerobic Gram-negative bacillus from the index blood culture, and did not withdraw consent before day 14. The non-inferiority margin was 10%; superiority was to be assessed if non-inferiority was shown, and was evaluated in both the main analysis population and in patients with at least one carbapenem-resistant organism causing bloodstream infection. Missing data were handled by imputing data. The trial was registered on &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (&lt;span&gt;&lt;span&gt;NCT03869437&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;) and is closed to new participants.&lt;h3&gt;Findings&lt;/h3&gt;513 participants were enrolled between Nov 12, 2019, and Oct 31, 2023 (210 [42%] female and 294 [58%] male). 256 patients were randomly assigned to cefiderocol and 257 were assigned to standard of care. Nine patients (six in the cefiderocol group and three in the standard-of-care group) were excluded from further analysis because they withdrew consent or their blood cultures did not grow an aerobic Gram-negative bacillus. Thus, 504 participants were included in the main analysis population. 20 (8%) of 250 patients in the cefiderocol group had died at 14 days compared with","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"112 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Household transmission of mpox in Africa: limited in adults but more prevalent in children","authors":"Oriol Mitjà, Michael Marks","doi":"10.1016/s1473-3099(25)00503-1","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00503-1","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"59 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}